8-K

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) September 20, 2012

CHROMADEX CORP.

 (Exact name of registrant as specified in its charter)

Delaware	000-53290	26-2940963
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10005 Muirlands Boulevard, Suite G, Irvine, California, 92618

(Address of principal executive offices, including zip code)

(949) 419-0288

 (Registrant's telephone number, including area code)

Copies to:

Harvey Kesner, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Phone: (212) 930-9700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01       REGULATION FD DISCLOSURE

On September 20, 2012, Chromadex Corporation (the “Company”) issued a press release with respect to certain test results pertaining to the impact of pterostilbene on blood pressure and other metabolic parameters in adults that were announced on September 20, 2012 by the American Heart Association, the abstract of such results is attached hereto as Exhibit 99.1.  A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information disclosed under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act, except as expressly set forth in such filing.

ITEM 9.01       FINANCIAL STATEMENTS AND EXHIBITS

(d)           Exhibits

Exhibit No.	Description
99.1	Abstract of the Impact Of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults, dated September 20, 2012
99.2	Press Release

SIGNATURES

                    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: September 20, 2012

CHROMADEX CORP.
By:	/s/ Frank L. Jaksch Jr.
Name:	Frank L. Jaksch Jr.
Title:	Chief Executive Officer

EX-99.1

Exhibit 99.1

Presentation Abstract
Session:	13-Poster Session II
	Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM
Presentation:	617 - Impact of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults
Location:	Regency
Pres. Time:	Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM
Category:	Nutrition and Hypertension
Keywords:	Hypertension; Clinical trials; Lipids
Author(s):	Daniel M Riche, Univ of Mississippi Sch of Pharmacy, Jackson, MS; David Deschamp, Michael E. Griswold, Univ of Mississippi Medical Ctr, Jackson, MS; Corey L. McEven, Cleveland Clinic, Cleveland, OH; Krista D. Riche, St. Dominic Hosp, Jackson, MS; Justin J Sherman, Univ of Mississippi Sch of Pharmacy, Jackson, MS; Marion R. Wofford, Univ of Mississippi Medical Ctr, Jackson, MS
Abstract:	Objective:  Pterostilbene is a polyphenol that is chemically related to resveratrol and commonly found in berries, such as blueberries.  The purpose of this trial was to evaluate the effect of pterostilbene on metabolic parameters. Methods:  The trial was a prospective, randomized, double-blind, placebo-controlled study of patients with a total cholesterol > 200 mg/dL and/or LDL > 100 mg/dL.  Patients were included if they were > 18  years old and on either no cholesterol therapy or cholesterol medication at a stable dose for at least 2 months prior to baseline laboratory.  Patients were excluded if they had significant hepatic, renal or GI tract disease or current overt cardiovascular disease; were receiving thiazolidinediones or fibric acids; were women who were pregnant or of reproductive potential.  Eighty subjects were divded equally into one of four groups: (1) pterostilbene 125 mg twice daily; (2) pterostilbene 50 mg twice daily; (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily; (4) matching placebo twice daily for 6-8 weeks.  Patients received identical couseling on lifestyle intervention.  Metabolic endpoints included blood pressure, body weight, and lipids.  Linear mixed models were used to examine changes in metabolic parameters over time within treatment groups and compare changes over time across groups.  Models were adjusted for age, sex, and race. Results:  The majority of pateitns completed the study (73/80; 91%).  The average age was 54 years.  The majority of patients were female (57/80; 71%), Caucasian (56/80; 70%), and had HTN (44/80; 55%).  Both systolic (-7.8 mmHg; p<0.01) and diastolic blood pressure (-7.3 mmHg; p<0.001) were reduced with high dose pterostilbene.  The only change in lipids was an increase in LDL with pterostilbene monotherapy (24.9 mg/dL; p<0.001) which was not seen with GE combination (p=0.47).  Presence of a baseline cholesterol medication appeared to attenuate LDL effects.  Patients not on cholesterol medication (n=51) exhibited minor weight loss with pterostilbene (-0.59 kg/m2; p=0.014). Conclusion:  Pterostilbene reduces blood pressure in adults.  Future studies should evaluate high dose pterostilbene with GE in a hypertensive population.  Clinicaltrials.gov identifier NCT 01267227.
Disclosures:	D.M. Riche: B. Research Grant (includes principal investigator, collaborator, or consultant and pending grants as well as grants already received); Modest; Chromadex: Principal Investigator.  D. Deschamp: None.  M.E. Griswold:  None.  C.L. McEwen: None.  K.D. Riche: None.  J.J. Sherman: None.  M.R. Wofford: None.

OASIS Helpdesk

Monday-Friday, 9 am - 5 pm CT

Phone: 1-217-398-1792

EX-99.2

Exhibit 99.2

Clinical Study Showed a Blueberry Antioxidant, pTeroPure® (pterostilbene), Significantly Reduced Blood Pressure in Adults

- Efficacy Data for ChromaDex®’s Patented pTeroPure® Presented at American Heart Association’s High Blood Pressure Research 2012 Scientific Sessions -

IRVINE, Calif. – September 20, 2012 – ChromaDex® Corporation (OTCBB: CDXC) announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure® (pterostilbene) significantly reduced blood pressure in adults. The findings from the study, the first clinical trial of the pure compound, were presented today at the American Heart Association’s High Blood Pressure Research 2012 Scientific Sessions.1 pTeroPure, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan, is a nature identical form of pterostilbene, an antioxidant found in blueberries.

“We saw reduced overall blood pressure in patients who received the high dose of pterostilbene,” said the study’s principle investigator, Daniel M. Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy. “The results of this study highlight that pterostilbene is a promising ingredient in the area of cardiometabolics.” 

Pterostilbene is believed by many experts to show great promise for supporting heart health,2,3,4,5,6 cognitive function,7,8anti-aging,9,10 weight loss and other metabolic disorders. Pterostilbene has superior biological activity,11,12,13,14,15better oral bioavailability16,17,18 and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity.19,20,21,22

The study, a double-blind, placebo-controlled trial, included 80 adults averaging 54 years of age with high cholesterol (total cholesterol of 200 or greater and/or LDL cholesterol of 100 or greater). Most participants were women (71%) and some had been diagnosed with high blood pressure (55%). The mean average baseline systolic blood pressure (BP) was 127.4 mmHg and the mean average baseline diastolic BP was 79.3 mmHG. The American Heart Association guidelines state that >119 mmHg systolic BP and >79 mmHg diastolic BP are classified as pre-hypertensive.23 Twice daily, participants received high (125 mg) doses of pterostilbene, low (50 mg) doses of pterostilbene, pterostilbene (50 mg) with grape extract (100 mg), or placebo. The investigators assessed participants’ blood pressure, body weight and blood lipids at the beginning and end of the study.

By the end of the study, participants in the high-dose pterostilbene group (250 mg/day) achieved significant reductions in BP compared to placebo: 7.8 mmHg in systolic BP (p < 0.01) and 7.3 mm Hg in diastolic BP (p < 0.001), without serious adverse events. The only change in lipids was an increase in LDL cholesterol with pTeroPure (24.9 mg/dL, p < 0.001), which was less among participants on cholesterol-lowering medication and was not seen among those who also received the grape extract. Participants not on cholesterol medication also achieved a minor average reduction in body weight (reduced body mass index 0.59 kg/m2) with pTeroPure. ChromaDex plans to conduct further studies specific for weight reduction to evaluate this trend.

“With high blood pressure affecting more than 76 million adults in the U.S.,24 we are thrilled that these findings show pTeroPure to be effective at reducing blood pressure,” said Frank Jaksch Jr., CEO and co-founder of ChromaDex. “With limited  non-prescription options to address this ‘silent killer,’ these results will allow pTeroPure to carry a claim of being ‘clinically proven,’ an attribute that should have a meaningful impact on demand for the ingredient.”

pTeroPure is the key novel ingredient in BluScience™, ChromaDex's recently launched line of dietary supplements. BluScience, is now available in more than 17,000 outlets in the U.S, including national drugstore chains, wholesalers and mass channel and internet distributors.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.

-1-

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Media Inquiries:

Chandler Chicco Agency

Keshia Cain, Media Specialist

310-309-1017

kcain@ccapr.com

ChromaDex Investor Contact:

The Del Mar Consulting Group, Inc.

Robert B. Prag, President

858-794-9500

bprag@delmarconsulting.com

or

Alex Partners, LLC

Scott Wilfong, President

425- 242-0891

Scott@alexpartnersllc.com

ChromaDex Contact:

Laura Carney, Executive Assistant

949-419-0288

laurac@chromadex.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

 

1 Riche DM, Deschamp D, Griswold ME, McEwen CL Riche KD, Sherman JJ, Wofford MR. Impact of pterostilbene on metabolic parameters in humans.  Poster presentation at: American Heart Association 2012 Scientific Sessions on High Blood Pressure Research.

 

2 Rimando AM, Nagmani R, Feller DR, and Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 53, 3403 (2005).

 

3 Pan Z, Agarwal AK, Xu T, Feng Q, Baerson SR, Duke SO, Rimando AM. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Med. Genomics. 1, 7 (2008).

 

4 Pons L. Agricultural Research/November-December 2006. This work is part of Plant Biological and Molecular Processes(#302) and Quality and Utilization of Agricultural Products (#306), two ARS National Programs described on the World Wide Web at www.nps.ars.usda.gov.

 

5 Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. Bioorg. Med. Chem. 16(7), 3800 (2008).

 

6 Park ES, Lim Y, Hong JT, Yoo HS, Lee CK, Pyo MY, Yun YP. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol. 53, 61 (2010).

-2-

 

7 Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).

 

8 Shukitt-Hale B, Lau FC, Joseph JA. Berry Fruit Supplementation and the Aging Brain. J. Agric. Food Chem. 56, 636 (2008).

 

9 Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).

 

10 Shukitt-Hale B, Lau FC, Joseph JA. Berry Fruit Supplementation and the Aging Brain. J. Agric. Food Chem. 56, 636 (2008).

 

11 Rimando AM, Nagmani R, Feller DR, and Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 53, 3403 (2005).

 

12 Perecko T, Jancinova V, Drabikova K, Nosal R, Harmatha J. Structure efficiency relationship in derivatives of stilbene. Comparison of resveratrol, pinosylvin and pterostilbene. Neuro. Endocrinol. Lett. 29(5), 802 (2008).

 

13 Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).

 

14 Billack B, Radkar V, Adiabouah C. In vitro evaluation of the cytotoxic and antiproliferative properties of resveratrol and several of its analogs. Cell. Mol. Biol. Lett. 13, 553 (2008).

 

15 Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, Li J, Wu CF. Effects of resveratrol and its derivatives on lipopolysaccharide induced microglial activation and their structure activity relationships. Chem. Biol. Interact. 174(1), 51 (2008).

 

16 Asensi M, Medina I, Ortega A, Carretero J, Carmen Bano M, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387 (2002).

 

17 Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1, 81 (2006).

 

18 Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. (2010 Nov 30. Epub ahead of print).

 

19 Asensi M, Medina I, Ortega A, Carretero J, Carmen Bano M, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387 (2002).

 

20 Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. (2010 Nov 30. Epub ahead of print).

 

21 Remsberg CM, Yáñez JA, Ohgami Y, VegaVilla KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother. Res. 22, 169 (2008).

 

22 Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jordá L, Estrela JM. Associationbetween pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 7, 37 (2005).

 

23Based on Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the complete JNC 7 report. Hypertension 2003;42:1206–52.

 

24 American Heart Association. Statistical Fact Sheet – Update 2012. High Blood Pressure www.heart.org/idc/groups/heart-public/.../ucm_319587.pdf. Accessed September 18, 2012.

**END**